About this trial
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Eligibility criteria
Qualifiers
Participants must be > 18 years old and with a life expectancy > 12 weeks.
Participants must have a Karnofsky performance status of ≥ 60.
Participants must have adequate renal function (creatinine < 1.5 mg/dL) before starting therapy. This tests must be performed within 60 days prior to Hyperpolarized Imaging scan.
Participants must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate the imaging examination or any disease that will obscure toxicity or dangerously alter response to the imaging agent.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Hyperpolarized Carbon C 13 Pyruvate
- Magnetic Resonance Imaging
- Radiation Therapy
- Chemotherapy
Treatment groups
Sponsors and collaborators
Susan Chang
Lead sponsor
University of California, San Francisco
Sponsor institution
National Cancer Institute (NCI)
Collaborator